Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
New deal strengthens Congenica’s presence in India
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Lupin is the 6th largest company in the Indian Pharmaceutical Market
He was appointed a Board member and the Chairman in 2012.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Biopharma and CROs to benefit from simplified access to global research sites
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
Subscribe To Our Newsletter & Stay Updated
